Sponsor content
6 result(s) found, displaying 1 to 6
-
Australian public assessment report (AusPar)Lytgobi (futibatinib) has been approved for the treatment of locally advanced or metastatic intrahepatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
-
Designation or determinationOrphan drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LYTGOBI futibatinib 4 mg tablet blister pack.
-
Prescription medicine registrationActive ingredients: futibatinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INQOVI 35/100 decitabine 35 mg and cedazuridine 100 mg tablet blister pack.
-
Prescription medicine decision summaryTGA decision: Inqovi 35/100 (decitabine and cedazuridine) is approved to treat adult patients with myelodysplastic syndromes and CMML.